Market Cap: $3.49B
XI
Xenon Pharmaceuticals Inc.
XENE
NASDAQ (NASDAQ Global Market)USD
Market Cap: $3.49B
Xenon Pharmaceuticals (Ticker: XENE) is making significant strides in the realm of epilepsy treatment following promising results from its Phase III clinical trials for azetukalner. The company announ…
Xenon Pharmaceuticals showcases promising advancements in drug development with Azetukalner, a medication aimed at treating neurological disorders, as evidenced by the strong Phase III clinical trial…
Xenon Pharmaceuticals Pioneers New Frontiers in Epilepsy Treatment with X-TOLE2 Trial Success Xenon Pharmaceuticals Inc. has achieved a significant milestone with its recent Phase 3 clinical trial, X-…
Xenon Pharmaceuticals Advances Seizure Treatment in Positive Phase 3 Trial Results Xenon Pharmaceuticals Inc. (NASDAQ:XENE) makes significant strides in developing innovative treatments for epilepsy,…
Biohaven’s Innovative Approach to Major Depressive Disorder Shows Promise In a recent development in the mental health treatment landscape, Biohaven Ltd. announces the outcomes of its Phase 2 proof-of…
Xenon Pharmaceuticals Enhances Focus on Drug Development Amidst Industry Earnings Reports Xenon Pharmaceuticals, a clinical-stage biopharmaceutical company, continues to strengthen its emphasis on dru…
Xenon Pharmaceuticals: Advancing Rare Disease Treatments Amid Market Dynamics Xenon Pharmaceuticals focuses on developing innovative treatments for rare diseases, and recent developments highlight its…
Xenon Pharmaceuticals Prepares for Earnings Announcement Amid Clinical Development Focus Xenon Pharmaceuticals is poised to announce its quarterly earnings on November 3, 2025, a significant event tha…
Xenon Pharmaceuticals Prepares for Earnings Report Amid Promising Growth in Neurological Treatments Xenon Pharmaceuticals is gearing up for its quarterly earnings report set to be released on August 1…